Key Points
- Michael Amoroso, CEO of Precision BioSciences, sold 34,799 shares on Jan. 22 at an average price of $4.17 for roughly $145,112, reducing his stake by about 15.07% to 196,154 shares worth ≈$817,962.
- Precision BioSciences recently reported a steep earnings miss (Q EPS of ($1.84) vs. ($0.31) expected) with virtually no revenue, a tiny market cap (~$56.4M) and mixed analyst views (average rating "Hold" despite a wide consensus price target listed at $60.00 and a Weiss Ratings "sell").
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 10,200 shares of Precision BioSciences stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total value of $41,106.00. Following the completion of the transaction, the insider owned 110,184 shares in the company, valued at approximately $444,041.52. This represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Precision BioSciences Trading Up 6.0%
Shares of DTIL stock opened at $4.25 on Friday. The business has a 50-day moving average of $4.59 and a 200 day moving average of $5.12. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. Precision BioSciences, Inc. has a 1-year low of $3.75 and a 1-year high of $8.82. The stock has a market capitalization of $56.36 million, a PE ratio of -0.51 and a beta of 1.20.
Precision BioSciences (NASDAQ:DTIL - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($1.53). Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $5.40 million. During the same period last year, the company posted ($2.25) EPS. As a group, sell-side analysts anticipate that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.
Institutional Investors Weigh In On Precision BioSciences
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Precision BioSciences during the 3rd quarter valued at about $72,000. Virtu Financial LLC bought a new position in Precision BioSciences in the third quarter worth about $84,000. GSA Capital Partners LLP purchased a new stake in Precision BioSciences in the third quarter worth about $98,000. Velan Capital Investment Management LP bought a new stake in Precision BioSciences during the 3rd quarter valued at approximately $110,000. Finally, Citadel Advisors LLC bought a new stake in Precision BioSciences during the 3rd quarter valued at approximately $122,000. 37.99% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $60.00.
Get Our Latest Stock Report on Precision BioSciences
Precision BioSciences Company Profile
(
Get Free Report)
Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company's pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.
Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
